JP2013520420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520420A5 JP2013520420A5 JP2012553942A JP2012553942A JP2013520420A5 JP 2013520420 A5 JP2013520420 A5 JP 2013520420A5 JP 2012553942 A JP2012553942 A JP 2012553942A JP 2012553942 A JP2012553942 A JP 2012553942A JP 2013520420 A5 JP2013520420 A5 JP 2013520420A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- benzothiazol
- ylamino
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 176
- 150000001875 compounds Chemical class 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 51
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- -1 azetidino Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010051920 Glomerulonephropathy Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000000729 antidote Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XSZGCGHXDKUWDX-UHFFFAOYSA-N 1-methyl-n-(2-morpholin-4-yl-2-oxoethyl)-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=CC=1C(=O)NCC(=O)N1CCOCC1 XSZGCGHXDKUWDX-UHFFFAOYSA-N 0.000 claims 1
- DAXPSZBDWZWCTP-UHFFFAOYSA-N 1-methyl-n-(2-morpholin-4-ylethyl)-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=CC=1C(=O)NCCN1CCOCC1 DAXPSZBDWZWCTP-UHFFFAOYSA-N 0.000 claims 1
- QEMNNHCYNIZMRJ-UHFFFAOYSA-N 1-methyl-n-(3-methylsulfonylpropyl)-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound CS(=O)(=O)CCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC2=C1 QEMNNHCYNIZMRJ-UHFFFAOYSA-N 0.000 claims 1
- IVHSUHQPSPUUOP-UHFFFAOYSA-N 1-methyl-n-(3-morpholin-4-yl-3-oxopropyl)-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=CC=1C(=O)NCCC(=O)N1CCOCC1 IVHSUHQPSPUUOP-UHFFFAOYSA-N 0.000 claims 1
- DBZAOKVXTMDLAO-CQSZACIVSA-N 1-methyl-n-[(2r)-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl]-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound O=C([C@H](NC(=O)C=1C=C2N=C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)N(C)C2=CC=1)C)N1CCN(C)CC1 DBZAOKVXTMDLAO-CQSZACIVSA-N 0.000 claims 1
- LBZGTCJCYUMPON-ZDUSSCGKSA-N 1-methyl-n-[(2s)-1-morpholin-4-yl-1-oxopropan-2-yl]-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound O=C([C@@H](NC(=O)C=1C=C2N=C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)N(C)C2=CC=1)C)N1CCOCC1 LBZGTCJCYUMPON-ZDUSSCGKSA-N 0.000 claims 1
- DXSZLMINZDNCBR-UHFFFAOYSA-N 1-methyl-n-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(OC(F)(F)F)=CC=C3N=2)=N2)C2=C1 DXSZLMINZDNCBR-UHFFFAOYSA-N 0.000 claims 1
- KPNSYIXTHOWAAT-UHFFFAOYSA-N 1-methyl-n-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(=CC=C3N=2)C(F)(F)F)=N2)C2=C1 KPNSYIXTHOWAAT-UHFFFAOYSA-N 0.000 claims 1
- UFEOYPYMABXXMY-UHFFFAOYSA-N 1-methyl-n-[2-(methylamino)-2-oxoethyl]-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCC(=O)NC)=NC2=C1 UFEOYPYMABXXMY-UHFFFAOYSA-N 0.000 claims 1
- JRQPFVSXLWBXPV-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1-ethyl-n-(2-fluoroethyl)benzimidazole-5-carboxamide Chemical compound FCCNC(=O)C1=CC=C2N(CC)C(NC=3SC4=CC(Cl)=CC=C4N=3)=NC2=C1 JRQPFVSXLWBXPV-UHFFFAOYSA-N 0.000 claims 1
- VEZQHDHGRQBASX-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1-ethyl-n-(2-methoxyethyl)benzimidazole-5-carboxamide Chemical compound COCCNC(=O)C1=CC=C2N(CC)C(NC=3SC4=CC(Cl)=CC=C4N=3)=NC2=C1 VEZQHDHGRQBASX-UHFFFAOYSA-N 0.000 claims 1
- FRLOLVZHVLIVJC-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1-methylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(Cl)=CC=C4N=3)=NC2=C1 FRLOLVZHVLIVJC-UHFFFAOYSA-N 0.000 claims 1
- YASJQFLLRYLNJM-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-(2-ethoxyethyl)-1-methylbenzimidazole-5-carboxamide Chemical compound C1=C(Cl)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOCC)=NC2=C1 YASJQFLLRYLNJM-UHFFFAOYSA-N 0.000 claims 1
- YWRUZPBCYLGEOS-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-(2-methoxyethyl)-1-methylbenzimidazole-5-carboxamide Chemical compound C1=C(Cl)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOC)=NC2=C1 YWRUZPBCYLGEOS-UHFFFAOYSA-N 0.000 claims 1
- OWIZHCHWMJBBMJ-NSHDSACASA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-[(2s)-1-(dimethylamino)-1-oxopropan-2-yl]-1-methylbenzimidazole-5-carboxamide Chemical compound C1=C(Cl)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)N[C@@H](C)C(=O)N(C)C)=NC2=C1 OWIZHCHWMJBBMJ-NSHDSACASA-N 0.000 claims 1
- XLYPLEDFVDPBRF-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-[2-(2-hydroxyethoxy)ethyl]-1-methylbenzimidazole-5-carboxamide Chemical compound OCCOCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(Cl)=CC=C4N=3)=NC2=C1 XLYPLEDFVDPBRF-UHFFFAOYSA-N 0.000 claims 1
- VWCLQSLVGVCOMO-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-[2-(dimethylamino)-2-oxoethyl]-1-methylbenzimidazole-5-carboxamide Chemical compound C1=C(Cl)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCC(=O)N(C)C)=NC2=C1 VWCLQSLVGVCOMO-UHFFFAOYSA-N 0.000 claims 1
- XUFWDFONRFQANP-OAHLLOKOSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-[2-[(3r)-3-methoxypyrrolidin-1-yl]-2-oxoethyl]-1-methylbenzimidazole-5-carboxamide Chemical compound C1[C@H](OC)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(Cl)=CC=C3N=2)=N2)C2=C1 XUFWDFONRFQANP-OAHLLOKOSA-N 0.000 claims 1
- XUFWDFONRFQANP-HNNXBMFYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-[2-[(3s)-3-methoxypyrrolidin-1-yl]-2-oxoethyl]-1-methylbenzimidazole-5-carboxamide Chemical compound C1[C@@H](OC)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(Cl)=CC=C3N=2)=N2)C2=C1 XUFWDFONRFQANP-HNNXBMFYSA-N 0.000 claims 1
- XXMSGTTYJKZFMD-UHFFFAOYSA-N 2-[(6-chloro-1,3-benzothiazol-2-yl)amino]-n-[3-(dimethylamino)-3-oxopropyl]-1-methylbenzimidazole-5-carboxamide Chemical compound C1=C(Cl)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCC(=O)N(C)C)=NC2=C1 XXMSGTTYJKZFMD-UHFFFAOYSA-N 0.000 claims 1
- RZOUNNWATKMVNU-UHFFFAOYSA-N 3-methyl-n-(2-morpholin-4-ylethyl)-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]imidazo[4,5-b]pyridine-6-carboxamide Chemical compound C=1N=C2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC2=CC=1C(=O)NCCN1CCOCC1 RZOUNNWATKMVNU-UHFFFAOYSA-N 0.000 claims 1
- VBMJBIIVNYRJNX-UHFFFAOYSA-N 6-methoxy-1-methyl-n-(2-morpholin-4-ylethyl)-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound COC1=CC=2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC=2C=C1C(=O)NCCN1CCOCC1 VBMJBIIVNYRJNX-UHFFFAOYSA-N 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- LFIBGEGLUNWRED-UHFFFAOYSA-N n-(2-ethoxyethyl)-1-(2-methoxyethyl)-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(CCOC)C4=CC=C(C=C4N=3)C(=O)NCCOCC)=NC2=C1 LFIBGEGLUNWRED-UHFFFAOYSA-N 0.000 claims 1
- UEHBRHKNCMOCRN-UHFFFAOYSA-N n-(2-ethoxyethyl)-1-ethyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(CC)C4=CC=C(C=C4N=3)C(=O)NCCOCC)=NC2=C1 UEHBRHKNCMOCRN-UHFFFAOYSA-N 0.000 claims 1
- NDSSJXKOTQNPKI-UHFFFAOYSA-N n-(2-ethoxyethyl)-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOCC)=NC2=C1 NDSSJXKOTQNPKI-UHFFFAOYSA-N 0.000 claims 1
- WYHLJSXAFREKKI-UHFFFAOYSA-N n-(2-ethylsulfonylethyl)-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCS(=O)(=O)CC)=NC2=C1 WYHLJSXAFREKKI-UHFFFAOYSA-N 0.000 claims 1
- RJLXBNUVBHFZMM-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound OCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC2=C1 RJLXBNUVBHFZMM-UHFFFAOYSA-N 0.000 claims 1
- IOSBWVOQKVEYFV-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound OCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=C1 IOSBWVOQKVEYFV-UHFFFAOYSA-N 0.000 claims 1
- BRRIUZRZJZEFRY-UHFFFAOYSA-N n-(2-methoxy-2-methylpropyl)-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCC(C)(C)OC)=NC2=C1 BRRIUZRZJZEFRY-UHFFFAOYSA-N 0.000 claims 1
- YNURDJJKPNZLMH-UHFFFAOYSA-N n-(2-methoxyethyl)-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOC)=NC2=C1 YNURDJJKPNZLMH-UHFFFAOYSA-N 0.000 claims 1
- QUIZKVBGZQKFJX-UHFFFAOYSA-N n-(2-methoxyethyl)-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOC)=NC2=C1 QUIZKVBGZQKFJX-UHFFFAOYSA-N 0.000 claims 1
- UVLWJOJJAQQXBX-UHFFFAOYSA-N n-(2-methoxyethyl)-3-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]imidazo[4,5-b]pyridine-6-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=NC=C(C=C4N=3)C(=O)NCCOC)=NC2=C1 UVLWJOJJAQQXBX-UHFFFAOYSA-N 0.000 claims 1
- XVMDKAXKEBKVPO-LLVKDONJSA-N n-[(2r)-1-(dimethylamino)-1-oxopropan-2-yl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)N[C@H](C)C(=O)N(C)C)=NC2=C1 XVMDKAXKEBKVPO-LLVKDONJSA-N 0.000 claims 1
- WZQMTCBNXVBXSL-SNVBAGLBSA-N n-[(2r)-2-hydroxypropyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NC[C@H](O)C)=NC2=C1 WZQMTCBNXVBXSL-SNVBAGLBSA-N 0.000 claims 1
- HECCFQJJEDUCOX-SNVBAGLBSA-N n-[(2r)-2-hydroxypropyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NC[C@H](O)C)=NC2=C1 HECCFQJJEDUCOX-SNVBAGLBSA-N 0.000 claims 1
- ABKAESRNRYAHKJ-NSHDSACASA-N n-[(2s)-1-(dimethylamino)-1-oxopropan-2-yl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)N[C@@H](C)C(=O)N(C)C)=NC2=C1 ABKAESRNRYAHKJ-NSHDSACASA-N 0.000 claims 1
- XVMDKAXKEBKVPO-NSHDSACASA-N n-[(2s)-1-(dimethylamino)-1-oxopropan-2-yl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)N[C@@H](C)C(=O)N(C)C)=NC2=C1 XVMDKAXKEBKVPO-NSHDSACASA-N 0.000 claims 1
- WZQMTCBNXVBXSL-JTQLQIEISA-N n-[(2s)-2-hydroxypropyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NC[C@@H](O)C)=NC2=C1 WZQMTCBNXVBXSL-JTQLQIEISA-N 0.000 claims 1
- QOXGBCLRUXCLJD-UHFFFAOYSA-N n-[2-(2-fluoroethoxy)ethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound FCCOCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC2=C1 QOXGBCLRUXCLJD-UHFFFAOYSA-N 0.000 claims 1
- LCTSITDUYKSJBX-UHFFFAOYSA-N n-[2-(2-hydroxyethoxy)ethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound OCCOCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC2=C1 LCTSITDUYKSJBX-UHFFFAOYSA-N 0.000 claims 1
- BJSHVWKLYLAKTP-UHFFFAOYSA-N n-[2-(2-hydroxyethoxy)ethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound OCCOCCNC(=O)C1=CC=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=C1 BJSHVWKLYLAKTP-UHFFFAOYSA-N 0.000 claims 1
- AYFAKGNOPLGJHT-UHFFFAOYSA-N n-[2-(2-methoxyethoxy)ethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOCCOC)=NC2=C1 AYFAKGNOPLGJHT-UHFFFAOYSA-N 0.000 claims 1
- JLDKODGNYQELDB-UHFFFAOYSA-N n-[2-(2-methoxyethoxy)ethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOCCOC)=NC2=C1 JLDKODGNYQELDB-UHFFFAOYSA-N 0.000 claims 1
- QTOLSKNUFLJUEO-UHFFFAOYSA-N n-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(OC(F)(F)F)=CC=C4N=3)=NC2=CC=1C(=O)NCC(=O)N1CCC(O)CC1 QTOLSKNUFLJUEO-UHFFFAOYSA-N 0.000 claims 1
- PSCQHHIOAGGTSV-UHFFFAOYSA-N n-[2-(dimethylamino)-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCC(=O)N(C)C)=NC2=C1 PSCQHHIOAGGTSV-UHFFFAOYSA-N 0.000 claims 1
- QCGGTVVSGLTYJW-UHFFFAOYSA-N n-[2-(dimethylamino)-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCC(=O)N(C)C)=NC2=C1 QCGGTVVSGLTYJW-UHFFFAOYSA-N 0.000 claims 1
- KZNLWKXCYRNUEJ-UHFFFAOYSA-N n-[2-(dimethylamino)-2-oxoethyl]-3-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]imidazo[4,5-b]pyridine-6-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=NC=C(C=C4N=3)C(=O)NCC(=O)N(C)C)=NC2=C1 KZNLWKXCYRNUEJ-UHFFFAOYSA-N 0.000 claims 1
- CPTVWSKOUUBYGU-OAHLLOKOSA-N n-[2-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1[C@H](N(C)C)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(OC(F)(F)F)=CC=C3N=2)=N2)C2=C1 CPTVWSKOUUBYGU-OAHLLOKOSA-N 0.000 claims 1
- MGFMROFNWGHLDW-OAHLLOKOSA-N n-[2-[(3r)-3-hydroxypiperidin-1-yl]-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=CC=1C(=O)NCC(=O)N1CCC[C@@H](O)C1 MGFMROFNWGHLDW-OAHLLOKOSA-N 0.000 claims 1
- DBOFDRVFFQCCEL-CQSZACIVSA-N n-[2-[(3r)-3-hydroxypyrrolidin-1-yl]-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=CC=1C(=O)NCC(=O)N1CC[C@@H](O)C1 DBOFDRVFFQCCEL-CQSZACIVSA-N 0.000 claims 1
- CPTVWSKOUUBYGU-HNNXBMFYSA-N n-[2-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(OC(F)(F)F)=CC=C3N=2)=N2)C2=C1 CPTVWSKOUUBYGU-HNNXBMFYSA-N 0.000 claims 1
- MGFMROFNWGHLDW-HNNXBMFYSA-N n-[2-[(3s)-3-hydroxypiperidin-1-yl]-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C=1C=C2N(C)C(NC=3SC4=CC(=CC=C4N=3)C(F)(F)F)=NC2=CC=1C(=O)NCC(=O)N1CCC[C@H](O)C1 MGFMROFNWGHLDW-HNNXBMFYSA-N 0.000 claims 1
- GNDFPFGXDPHXPE-HNNXBMFYSA-N n-[2-[(3s)-3-methoxypyrrolidin-1-yl]-2-oxoethyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1[C@@H](OC)CCN1C(=O)CNC(=O)C1=CC=C(N(C)C(NC=2SC3=CC(=CC=C3N=2)C(F)(F)F)=N2)C2=C1 GNDFPFGXDPHXPE-HNNXBMFYSA-N 0.000 claims 1
- IJSFTLRXSMBLKX-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethoxy]ethyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCOCCN(C)C)=NC2=C1 IJSFTLRXSMBLKX-UHFFFAOYSA-N 0.000 claims 1
- KKZNBFOUHGSGIM-UHFFFAOYSA-N n-[3-(dimethylamino)-3-oxopropyl]-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCC(=O)N(C)C)=NC2=C1 KKZNBFOUHGSGIM-UHFFFAOYSA-N 0.000 claims 1
- WQYAOGYRBPSHQR-UHFFFAOYSA-N n-[3-(dimethylamino)-3-oxopropyl]-1-methyl-2-[[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2SC(NC=3N(C)C4=CC=C(C=C4N=3)C(=O)NCCC(=O)N(C)C)=NC2=C1 WQYAOGYRBPSHQR-UHFFFAOYSA-N 0.000 claims 1
- GFUUZZKVJMDQLI-UHFFFAOYSA-N n-ethyl-6-fluoro-1-methyl-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]benzimidazole-5-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2SC(NC3=NC=4C=C(C(=CC=4N3C)F)C(=O)NCC)=NC2=C1 GFUUZZKVJMDQLI-UHFFFAOYSA-N 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30572410P | 2010-02-18 | 2010-02-18 | |
| US61/305,724 | 2010-02-18 | ||
| JO47/2011 | 2011-02-03 | ||
| JOP20110047 | 2011-02-03 | ||
| PCT/US2011/024311 WO2011103018A1 (en) | 2010-02-18 | 2011-02-10 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520420A JP2013520420A (ja) | 2013-06-06 |
| JP2013520420A5 true JP2013520420A5 (enExample) | 2014-03-20 |
| JP5814948B2 JP5814948B2 (ja) | 2015-11-17 |
Family
ID=62839064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553942A Active JP5814948B2 (ja) | 2010-02-18 | 2011-02-10 | 置換縮合イミダゾール誘導体、その医薬組成物、及び使用の方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12091407B2 (enExample) |
| EP (1) | EP2536285B1 (enExample) |
| JP (1) | JP5814948B2 (enExample) |
| KR (1) | KR101837759B1 (enExample) |
| CN (1) | CN102762101B (enExample) |
| AU (1) | AU2011218316B2 (enExample) |
| CA (1) | CA2789950C (enExample) |
| DK (1) | DK2536285T3 (enExample) |
| EA (1) | EA201290808A1 (enExample) |
| ES (1) | ES2679918T3 (enExample) |
| MX (1) | MX339243B (enExample) |
| NZ (1) | NZ602395A (enExample) |
| SG (1) | SG182629A1 (enExample) |
| WO (1) | WO2011103018A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2789950C (en) | 2010-02-18 | 2018-09-04 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| WO2012094580A2 (en) * | 2011-01-07 | 2012-07-12 | High Point Pharmaceuticals, Llc | Compounds that modulate oxidative stress |
| ES2784244T3 (es) * | 2013-12-18 | 2020-09-23 | Glaxosmithkline Ip Dev Ltd | Reguladores de Nrf2 |
| WO2015175845A1 (en) * | 2014-05-15 | 2015-11-19 | Peloton Therapeutics, Inc. | Benzimidazole derivatives and uses thereof |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| WO2020117886A1 (en) * | 2018-12-07 | 2020-06-11 | Vtv Therapeutics Llc | Methods of inhibiting osteoclastogenesis and osteoclast activity |
| MX2021008071A (es) * | 2019-01-18 | 2021-09-08 | Vtv Therapeutics Llc | Derivados de imidazol fusionado sustituido y métodos de tratamiento de la anemia de células falciformes y complicaciones relacionadas. |
| BR112021020055A2 (pt) | 2019-04-12 | 2021-12-07 | Mitobridge Inc | Indutores de hmox1 |
| CA3170063A1 (en) | 2020-02-05 | 2021-08-12 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives and methods of treating refractive ocular disorders |
| CN117658832A (zh) * | 2022-09-08 | 2024-03-08 | 史梦婷 | 一种n，n-二甲基双氨乙基醚的制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5300434A (en) | 1987-11-06 | 1994-04-05 | Washington Research Foundation | Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide |
| US5320970A (en) | 1987-11-06 | 1994-06-14 | Washington Research Foundation | Detection of collagen degradation in vivo |
| US4973666A (en) | 1987-11-06 | 1990-11-27 | Washington Research Foundation | Peptide fragments containing HP and LP cross-links |
| US5561134A (en) | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| FR2716192B1 (fr) | 1994-02-17 | 1996-04-12 | Rhone Poulenc Agrochimie | Dérivés de 2-imidazoline-5-ones fongicides. |
| CA2132690A1 (en) * | 1994-09-22 | 1996-03-23 | Dean Willis | Control and modulation of inflammatory response in humans in need of such control and modulation |
| US6562854B2 (en) | 1994-12-14 | 2003-05-13 | Axys Pharmaceuticals, Inc. | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders |
| CA2285454A1 (en) | 1997-04-07 | 1998-10-15 | Axys Pharmaceuticals Corporation | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| WO1999026932A1 (en) | 1997-11-26 | 1999-06-03 | Axys Pharmaceuticals, Inc. | By amidino group substituted heterocyclic derivatives and their use as anticoagulants |
| JP2000038387A (ja) | 1998-05-19 | 2000-02-08 | Sankyo Co Ltd | 三環性カルバペネム化合物 |
| WO2000005223A2 (en) | 1998-07-23 | 2000-02-03 | Astrazeneca Ab | Heterocyclic derivatives and their use as integrin inhibitors |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| HK1047582B (zh) * | 1999-06-23 | 2005-03-04 | 萨诺费－阿文蒂斯德国有限公司 | 取代的苯並咪唑 |
| US8639009B2 (en) | 2000-10-11 | 2014-01-28 | Imatx, Inc. | Methods and devices for evaluating and treating a bone condition based on x-ray image analysis |
| US7238813B2 (en) | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
| SE0101387D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| JP2003344971A (ja) | 2002-05-24 | 2003-12-03 | Konica Minolta Holdings Inc | ハロゲン化銀写真感光材料 |
| CN1674942A (zh) * | 2002-06-21 | 2005-09-28 | 联邦高等教育系统匹兹堡大学 | 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途 |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| SE0203070D0 (en) | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
| FR2851563B1 (fr) | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| CA2562833A1 (en) | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| EP1838690A2 (en) | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
| US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| DE102005003362A1 (de) | 2005-01-25 | 2006-07-27 | Wella Aktiengesellschaft | Kationische Azacyanin-Farbstoffe enthaltende Färbemittel |
| US7517893B2 (en) | 2005-05-20 | 2009-04-14 | The University Of North Carolina At Chapel Hill | Bichalcophenes and their prodrugs as antiprotozoal agents |
| US20100249175A1 (en) | 2005-12-02 | 2010-09-30 | Wilson W David | Dicationic compounds which selectively recognize G-quadruplex DNA |
| CN102633783A (zh) * | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| US20090075983A1 (en) | 2006-02-14 | 2009-03-19 | Dan Peters | Novel Diazabicycloalkane Derivatives and Their Medical Use |
| JP5291471B2 (ja) | 2006-02-15 | 2013-09-18 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| EP2653873B8 (en) | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| CN103087043A (zh) | 2007-03-16 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂 |
| WO2008153701A1 (en) | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2008151437A1 (en) * | 2007-06-14 | 2008-12-18 | Osta Biotechnologies | Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system |
| KR20100042287A (ko) | 2007-07-31 | 2010-04-23 | 쉐링 코포레이션 | 항암요법으로서의 항-유사분열제 및 아우로라 키나제 억제제 조합물 |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009051796A2 (en) | 2007-10-17 | 2009-04-23 | The University Of North Carolina At Chapel Hill | 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents |
| UA103013C2 (uk) | 2007-12-06 | 2013-09-10 | Тиботек Фармасьютикелз | Амідні сполуки як активатори противірусних препаратів |
| JP2009149589A (ja) | 2007-12-24 | 2009-07-09 | Dnp Fine Chemicals Co Ltd | 非対称モノアザメチンシアニンの製造方法 |
| ME03529B (me) | 2008-01-11 | 2020-04-20 | Reata Pharmaceuticals Inc | Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti |
| WO2009116074A2 (en) | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Substituted benzimidazoles as cannabinoid modulator |
| US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| WO2009133127A1 (en) | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Fused bicyclic compounds and use thereof as pi3k inhibitors |
| WO2009134850A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| GB0810981D0 (en) | 2008-06-16 | 2008-07-23 | Univ Leuven Kath | Novel compounds |
| US20110257171A1 (en) | 2008-07-18 | 2011-10-20 | Sanofi-Aventis | Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| TW201008938A (en) | 2008-07-18 | 2010-03-01 | Sanofi Aventis | Novel triazolo[4,3-a]pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors |
| FR2933982A1 (fr) | 2008-07-18 | 2010-01-22 | Sanofi Aventis | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| CN102361857B (zh) | 2008-09-26 | 2015-09-16 | 默沙东公司 | 可用作抗糖尿病剂的环状苯并咪唑衍生物 |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| AU2009322393B2 (en) | 2008-12-03 | 2017-02-02 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| EP2401273A1 (en) | 2009-02-27 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CA2789950C (en) | 2010-02-18 | 2018-09-04 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| WO2012094580A2 (en) | 2011-01-07 | 2012-07-12 | High Point Pharmaceuticals, Llc | Compounds that modulate oxidative stress |
| WO2013057592A2 (en) | 2011-09-14 | 2013-04-25 | King Abdullah University Of Science And Technology | Treatment of sickle cell disease |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
| AU2015233336B2 (en) | 2014-03-21 | 2019-02-28 | Centre National De La Recherche Scientifique (Cnrs) | Fumarate-CO-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation |
| US10039513B2 (en) | 2014-07-21 | 2018-08-07 | Zebra Medical Vision Ltd. | Systems and methods for emulating DEXA scores based on CT images |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| WO2020117886A1 (en) | 2018-12-07 | 2020-06-11 | Vtv Therapeutics Llc | Methods of inhibiting osteoclastogenesis and osteoclast activity |
| MX2021008071A (es) | 2019-01-18 | 2021-09-08 | Vtv Therapeutics Llc | Derivados de imidazol fusionado sustituido y métodos de tratamiento de la anemia de células falciformes y complicaciones relacionadas. |
| BR112021020055A2 (pt) | 2019-04-12 | 2021-12-07 | Mitobridge Inc | Indutores de hmox1 |
| CA3170063A1 (en) | 2020-02-05 | 2021-08-12 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives and methods of treating refractive ocular disorders |
-
2011
- 2011-02-10 CA CA2789950A patent/CA2789950C/en active Active
- 2011-02-10 KR KR1020127023193A patent/KR101837759B1/ko active Active
- 2011-02-10 EA EA201290808A patent/EA201290808A1/ru unknown
- 2011-02-10 EP EP11745064.3A patent/EP2536285B1/en active Active
- 2011-02-10 WO PCT/US2011/024311 patent/WO2011103018A1/en not_active Ceased
- 2011-02-10 JP JP2012553942A patent/JP5814948B2/ja active Active
- 2011-02-10 DK DK11745064.3T patent/DK2536285T3/en active
- 2011-02-10 SG SG2012053732A patent/SG182629A1/en unknown
- 2011-02-10 ES ES11745064.3T patent/ES2679918T3/es active Active
- 2011-02-10 NZ NZ602395A patent/NZ602395A/en not_active IP Right Cessation
- 2011-02-10 MX MX2012009628A patent/MX339243B/es active IP Right Grant
- 2011-02-10 AU AU2011218316A patent/AU2011218316B2/en active Active
- 2011-02-10 CN CN201180009915.3A patent/CN102762101B/zh active Active
-
2023
- 2023-04-03 US US18/295,133 patent/US12091407B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| JP2014531449A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2014513139A5 (enExample) | ||
| SI1539753T1 (sl) | Spojine pirazolo(3,4-B)piridina in njihova uporaba kot inhibitorji fosfodiesteraze | |
| JP2018501315A5 (enExample) | ||
| MX2010001677A (es) | Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli | |
| JP2012507567A5 (enExample) | ||
| JP2010513283A (ja) | 新規なオキサジアゾール化合物 | |
| JP2013500247A5 (enExample) | ||
| CA3021068A1 (en) | Combinations and methods comprising a capsid assembly inhibitor | |
| JP2013523614A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| CN105246889B (zh) | 氟化整联蛋白拮抗剂 | |
| JP2015514808A5 (enExample) | ||
| JP2009534405A5 (enExample) | ||
| JP2014525426A5 (enExample) | ||
| JP2011526926A5 (enExample) | ||
| JP2014514349A5 (enExample) | ||
| JP2012502067A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| RU2016141569A (ru) | Комбинации |